Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

This study developed a smart PVA-TPE/HA-AMP/SF/ALG wound dressing that shows promise in infected wound healing by providing bacterial resistance, promoting cell proliferation, and modulating inflammation through various signaling pathways, potentially reducing scar formation.

This study found that alopecia areata patients had higher baseline interleukin levels, which significantly decreased with tofacitinib treatment, though this change did not correspond to disease severity improvement.

This study explored the use of an AI-driven device, HairMetrix, to quantitatively assess the effects of PRP treatments on scalp health in two Caucasian women with androgenetic alopecia, reporting increases in average hair width and follicle count after one treatment.

This study provides evidence that innate lymphoid cells-type 1 can induce alopecia areata in human hair follicles, challenging the view that it is solely a CD8+ T cell-driven autoimmune disease.

This study found that their newly developed ADRL framework significantly improved the accuracy of scalp tissue layer segmentation in HR-MR images compared to existing methods.

This study suggests that interleukin-15 plays a complex role in alopecia areata, potentially contributing to immune infiltration while also protecting against hair follicle immune privilege collapse and promoting hair growth.

In a murine model of androgenetic alopecia, this study found that the newly designed IGF-1 biomimetic peptide Ac-GFFY-IGF led to faster and superior hair regrowth compared to minoxidil, suggesting potential for improved human therapies.

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

This study reported that tofacitinib may be a promising treatment for alopecia areata in adolescents, showing significant hair regrowth with mild adverse effects in a retrospective review.

In this study, the use of Biofibre hair implants showed significant improvements in scalp coverage and Hamilton scale grading for 97.94% of male and female patients with androgenetic alopecia after two years, with minimal and manageable side effects reported.

This study found that patients with Alopecia Areata had significantly higher levels of the chemokines MIG and IP-10 compared to healthy controls, suggesting these molecules may serve as potential biomarkers for diagnosing and monitoring the condition.

ALDOA levels drop in hair cells during hair loss.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This study reported that IL-15 promotes human hair growth and protects hair follicle immune privilege, potentially stabilizing alopecia areata treatment outcomes when selectively stimulating IL-15Rα signaling.

This study found that Imaging Mass Cytometry effectively visualizes multiple biomarkers in alopecia areata, enhancing analysis of immune cell and tissue interactions in hair pathology.

ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.

In this study, researchers found potential evidence of inducible skin-associated lymphoid tissue (iSALT) in alopecia areata patients undergoing topical immunotherapy, which may suggest an essential role in treatment efficacy.

This study found that mycophenolate mofetil was well tolerated and effective as a second-line treatment for autoimmune hepatitis in patients who were intolerant to azathioprine.

This case report suggests a possible association between long-term finasteride use for male pattern baldness and the development of cataracts and intraoperative floppy-iris syndrome in a patient.

This study found that the WIF1 gene may play a crucial role in hair follicle growth and development in Angora rabbits by regulating specific genes and proteins.

This study found that patients with alopecia areata had significantly higher systemic immune-inflammation index levels compared to healthy controls, regardless of the disease's severity.

In this study, single fibrinogen/LDL apheresis showed a significant improvement in speech perception for patients with plasma fibrinogen concentrations over 295 mg/dL compared to standard treatment for sudden sensorineural hearing loss.

This article reviews the potential for α-difluoromethylornithine to help control hair growth and prevent cancer, but it does not present new clinical results.

This vodcast discusses various tools for assessing the severity of alopecia areata, emphasizing the importance of considering psychosocial impacts alongside physical symptoms.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

This study found that targeting androgen receptors with prostate cancer drugs ARN509 and finasteride induced remission and increased survival in a leukemia mouse model, suggesting a potential new treatment approach for acute myeloid leukemia.

This study found that a new treatment candidate may effectively prevent and promote recovery from chemotherapy-induced alopecia by normalizing apoptosis and reducing inflammation in cancer patients.